Loading viewer...
investor_presentation
Format: PDF investor_presentation
January 13 2020Waters Corporation Management Presentation J.P. Morgan 38th Annual Healthcare Conference Chris O’Connell, Chairman & CEO
2020Waters Corporation
Management Presentation
J.P. Morgan 38th Annual Healthcare Conference
Chris O’Connell, Chairman & CEO2 ©2020 Waters CorporationThis presentation may contain “forward -looking” statements regarding future results and events. For this purpose, any statements that are not statements of
historical fact may be deemed forward -looking statements. Without limiting the foregoing, the words, “may”, will”, “should”, “f eels”, “believes”, “anticipates”,
“plans”, “expects”, “intends”, “suggests”, “appears”, “estimates”, “projects”, and similar expressions, whether in the negati ve or affirmative, are intended to
identify forward -looking statements.
Forward -looking statements are based on current expectations and assumptions and currently available data and are neither predic tions nor guarantees of
future events or performance. You should not place undue reliance on forward -looking statements, which speak only as of the dat e hereof and should not
be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this presentation. We do not undertake to
update or revise any forward -looking statements after they are made, whether as a result of new information, future events, or o therwise, except as required
by applicable law. The Company’s actual future results may differ significantly from the results discussed in the forward -looking statements within this
presentation for a variety of reasons, including and without limitation, foreign exchange rate fluctuations potentially affec ting translation of the Company’s
future non -U.S. operating results; the impact on demand for the Company’s products among the Company’s various market sectors or geographies from
economic, sovereign and political uncertainties, particularly regarding the effect of new or proposed tariff or trade regulat ions or changes in interpretation or
enforcement of existing regulations; the effect on the Company’s financial results from the United Kingdom voting to exit the European Union; fluctuations in
expenditures by the Company’s customers, in particular large pharmaceutical companies; introduction of competing products by other companies and loss
of market share; pressures on prices from competitors and/or customers; regulatory, economic and competitive obstacles to new product introductions;
other changes in demand for the Company’s products from the effect of mergers and acquisitions by the Company’s customers; in creased regulatory
burdens as the Company’s business evolves, especially with respect to the U.S. Food and Drug Administration and U.S. Environm ental Protection Agency,
among others; impact of the newly enacted tax reform legislation in the U.S.; shifts in taxable income in jurisdictions with different effective tax rates; the
outcome of tax examinations or changes in respective country legislation affecting the Company’s effective tax rate; the effe ct of the adoption of new
Preview truncated — download the full document for the complete content.
conference
22 Pages
investor_presentation
32 Pages
SAP®